Eestech Inc
Change company Symbol lookup
Select an option...
EESH Eestech Inc
GRTS Gritstone bio Inc
QTWO Q2 Holdings Inc
DNAB Social Capital Suvretta Holdings Corp II
UPST Upstart Holdings Inc
GILT Gilat Satellite Networks Ltd
LAIXY LAIX Inc
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
OXBR Oxbridge Re Holdings Ltd
NVO Novo Nordisk A/S
Go

Industrials : Machinery |
Company profile

EESTech, Inc. is a development-stage company. The Company is focused on providing mine site waste management solutions through the application of processing capabilities. The Company seeks to deliver remediation and reclamation services to the mining industry. Its patent pending reclamation and remediation services use process technologies to recover resources from mine site waste and process slag to produce a smelt-ready concentrate to produce metals/alloy and specialty inert sand products for multiple downstream applications. Its processing systems include waste resource agglomeration module (WRAM), inductosmelt reduction furnace (IRF) and ThermaSand. Its platform agglomerates recovered materials sourced from course discard dumps, fines dams and processing waste to produce commercially usable products in the form of WRAM ROX. Its IRF is designed to continuously smelt non-conductive materials, ores, concentrates or melt metals and glass, ranging in size from powder to lumps.

Closing Price
$0.10
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.10
Day's Low
0.10
Volume
30,000

American Well stock sinks to record low, torpedoed by Teladoc's dire outlook

2:07 pm ET April 28, 2022 (MarketWatch)
Print

By Tomi Kilgore

Accolade, Health Catalyst shares also dive to new lows

Shares of American Well Corp. plumbed record lows Thursday, dragged down by a brutally disappointing outlook from fellow online health care services provider, and market leader Teladoc Inc.

Teladoc's stock plummeted 44.4% in afternoon trading to levels not seen since November 2017, or more than two years before the start of the COVID-19 pandemic, after the company slashed its earnings outlook and recorded a massive impairment charge.

Also read: Teladoc's 'quarter for the bears' sparks and exodus of bulls.

That sent the shares of American Well, which Stifel Nicolaus analyst David Grossman said was the closest competitor to Teladoc, plunging 11.4%.

"While [American Well] is pursuing a different strategy (more platform focused than services focused), visit revenue and behavioral health services are material elements of their mix, they are also vulnerable to these market dynamics," Grossman wrote in a note to clients.

Grossman has rated American Well at hold since December 2020, and currently has a $5 stock price target.

Boston-based American Well went public at the height of the pandemic in September 2020, with its upsized initial public offering pricing at $18 a share, well above the expected range. The stock closed its first day of trading 28.2% above the IPO price, then rallied to a record close of $42.80, or 137.8% above the IPO price, on Jan. 27, 2021.

It's been downhill ever since, with the stock now trading about 83% below its IPO price. The stock has lost 49.7% year to date, while the S&P 500 index has shed 10.2%.

The company is scheduled to report first-quarter results on May 9, after the closing bell. For the fourth quarter, the company beat profit and revenue expectations, but provided 2022 revenue outlook that was below analyst expectations at that time.

American Well's stock wasn't the only one suffering at the hands of Teladoc, as shares of Accolade Inc. (ACCD) dove 11.7% to a record low, and Health Catalyst Inc. (HCAT) dropped 1.5%, also to a record low.

-Tomi Kilgore

	

(END) Dow Jones Newswires

April 28, 2022 14:07 ET (18:07 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.